Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients With Locally Advanced Head and Neck Cancer

Abstract

Depending on the criteria used to assess hearing loss due to treatment, differences in ototoxicity between CRT-IA and CRT-IV were found in favor of CRT-IA. It is desirable to specify hearing loss criteria toward frequencies vital for speech perception, and to refine grading scales to reveal subtle and clinically relevant dissimilarities in ototoxicity between different treatment protocols.

Protective effects of sodium thiosulfate for cisplatin-mediated ototoxicity in patients with head and neck cancer

“…In the present study, the median dose per infusion of cisplatin was 111 mg, less than 80 mg/m 2 . In contrast, in the cases of Madasu et al and Zuur et al, who followed the RADPLAT protocol, the dose per infusion of cisplatin was 150 mg/m 2 [10,11]. The median dose per infusion of cisplatin was 267 mg/m 2 in the report by Zuur et al [11].…”

“…On the other hand, in our data, the mean thresholds of the AC after CRT-IA at frequencies below 8 kHz were almost the same as those before CRT-IA. Zuur et al also reported hearing loss caused by intra-arterial cisplatin chemoradiation, particularly at ultra-high frequencies [11]. In their study, the mean total threshold shift at PTA AC 8, 10, and 12.5 kHz was 20.4 dB for CRT-IA.…”

“…The present study showed that the mean total threshold shift at PTA AC 8, 10, and 12 kHz was only 6.9 dB for CRT-IA. STS was administered in the cases studied by Madasu et al and Zuur et al [10,11]. The relatively lesser extent of hearing deterioration in our regimen may be explained by the use of a lower dose of cisplatin than used in RADPLAT.…”

Care of Pediatric Oncology Patients After Continuous Hyperthermic Peritoneal Perfusion

“…19,20 In our experience, despite lengthy surgical procedures, children are typically extubated within 12 hours of surgery.…”

“…A simultaneous intravenous infusion of sodium thiosulfate was given to inactivate any cisplatin that might enter the systemic circulation and to prevent side effects of systemic cisplatin such as renal failure, hearing loss, hair loss, nausea, and vomiting. 19 Constant physical A 6-year-old boy had a history of chronic constipation, acute abdominal pain, and abdominal distension. Computed tomography revealed peritoneal carcinomatosis and massive ascites with no renal or hepatic involvement.…”